SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility and intense social media debate after President Trump publicly endorsed the company, an move that community members are interpreting as both a strategic signal of long-term government backing and an attempt to counter recent aggressive short-selling campaigns led by figures like Michael Burry. While bulls view the endorsement and embedded defense contracts as a long-term catalyst, skeptics are actively questioning the ethics of the executive intervention and debating the competitive threat posed by emerging AI rivals.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is capturing market attention as investors weigh its latest financial update, which highlights a strategic transition toward production execution, a 30,000-unit shipment guidance for 2026, and a strengthened $430 million cash position. While the community is actively debating the company's valuation and the timeline for material revenue, bullish sentiment is being driven by perceived deep-seated connections to major AI infrastructure players and an increasing confidence that the firm's photonic interposer technology is poised to address critical industry bottlenecks.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether the stock is a deep-value opportunity or a long-term play against concerns of AI-driven obsolescence. Community members are actively discussing potential short squeezes, management's buyback strategies, and the competitive impact of Anthropic, with many bullish investors holding for the long term despite current volatility.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is currently experiencing intense volatility following strong quarterly earnings, with a fierce debate unfolding between investors betting on AI-driven revenue acceleration and skeptics concerned about high valuations and competitive threats from emerging AI models. The community is actively discussing the stock's sharp price swings and divided perspectives on its long-term viability in an evolving SaaS landscape, with many traders keeping a close watch on key support levels as they navigate the broader market's uncertainty.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing massive social media engagement and high-volume price action driven by investor excitement over its "Nvidia-adjacent" foundry partnerships and the potential for its proprietary EO polymer technology to become a standard in high-speed AI data infrastructure. Community sentiment remains polarized, with bulls tracking upcoming industry conferences and technical integration milestones, while bears point to the company's long-term history of pre-revenue status and recurring dilution concerns.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow (NOW) is experiencing significant downward pressure as market sentiment shifts due to concerns over AI integration and increased competition from emerging AI models. While bulls highlight strong fundamental growth and ServiceNow's partnership with Anthropic as long-term tailwinds, the community is currently debating whether this recent price action represents a generational buying opportunity or a structural shift in the software-as-a-service (SaaS) business model.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense volatility and heavy volume as traders react to a new multi-million dollar order for its 800G data center transceivers, fueling intense debates between momentum-driven bulls and short-sellers citing valuation concerns. The community is actively tracking the stock's role in the broader AI infrastructure buildout while debating whether this latest contract signals sustainable growth or a temporary rally in an overextended sector.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is capturing significant investor attention as shares experience high volatility ahead of a pivotal corporate update regarding the DENALI clinical trial. The community remains heavily divided, with some investors betting on a potential buyout or institutional accumulation due to the company's substantial cash position, while others express concerns over clinical trial risks and recent insider movements.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing intense community debate centered on significant institutional short interest and ongoing frustration over the lack of major strategic acquisition news. Investors are actively discussing the impact of dark pool trading volumes and debating whether to vote against the CEO's proposed compensation package as they watch for potential signs of a short squeeze.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors focus on its pivot toward domestic heavy rare earth metallization and magnets to meet defense-sector demand, supported by high-profile board appointments and defense contract news. The community is actively debating the company's long-term potential as a critical U.S. supply chain supplier versus concerns regarding its pre-revenue status and recent volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are covering the company, Marketbeat...

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK...

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation...

Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 6.9% - What's Next?

Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Up 6.9% - Should You Buy...

Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9% - Still a Buy?

Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9% - Time to Buy...

HC Wainwright Reaffirms Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX)

HC Wainwright reissued a "buy" rating and issued a $34.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday...

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that the last participant has been randomized and dosed in the pivotal Phase 3 LUCIDITY clinical trial of...

Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says

Guggenheim upped their price target on shares of Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday...

Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX

Maven Securities LTD purchased a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the third quarter, according to the company in its most recent disclosure with the...

First Light Asset Management LLC Purchases Shares of 3,355,882 Amylyx Pharmaceuticals, Inc. $AMLX

First Light Asset Management LLC purchased a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with...

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Current Price	$16.64
Prev Close	$17.32
Open	$17.27
Dividend Yield	0.00%
50-Day Moving Average	$14.41
Beta	1.73
Avg. Volume	1.06M
PE Ratio	-11.15

52-Week High	$17.49
52-Week Low	$3.42
Market Capitalization	$1.91B
EPS (Annual)	-$1.53
Price to Book	6.23
Revenue Per Employee	$0.00

AMLX
Amylyx Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AMLX News

AMLXAmylyx Pharmaceuticals Inc